These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2706010)

  • 21. Sulfaquinoxaline inhibition of vitamin K epoxide and quinone reductase.
    Preusch PC; Hazelett SE; Lemasters KK
    Arch Biochem Biophys; 1989 Feb; 269(1):18-24. PubMed ID: 2916837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of hydroxyvitamin K by vitamin K epoxide reductase of warfarin-resistant rats.
    Fasco MJ; Preusch PC; Hildebrandt E; Suttie JW
    J Biol Chem; 1983 Apr; 258(7):4372-80. PubMed ID: 6833262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect.
    Thijssen HH; Janssen YP
    J Pharmacol Exp Ther; 1994 Aug; 270(2):554-8. PubMed ID: 8071848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro: kinetics and warfarin inhibition.
    Wilson CR; Sauer JM; Carlson GP; Wallin R; Ward MP; Hooser SB
    Toxicology; 2003 Aug; 189(3):191-8. PubMed ID: 12832152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion of vitamin K epoxide to hydroxyvitamin K by liver microsomes from warfarin-resistant rats.
    Nutr Rev; 1983 Aug; 41(8):253-4. PubMed ID: 6355923
    [No Abstract]   [Full Text] [Related]  

  • 26. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat.
    Mosterd JJ; Thijssen HH
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1081-5. PubMed ID: 1545379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase.
    Creedon KA; Suttie JW
    Thromb Res; 1986 Oct; 44(2):147-53. PubMed ID: 3787564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver.
    Begent LA; Hill AP; Steventon GB; Hutt AJ; Pallister CJ; Cowell DC
    J Pharm Pharmacol; 2001 Apr; 53(4):481-6. PubMed ID: 11341364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The characterization of potent novel warfarin analogs.
    Kerr JS; Li HY; Wexler RS; Robinson AJ; Robinson CS; Boswell GA; Krauthauser C; Harlow PP
    Thromb Res; 1997 Oct; 88(2):127-36. PubMed ID: 9361366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of coumarin action: sensitivity of vitamin K metabolizing enzymes of normal and warfarin-resistant rat liver.
    Hildebrandt EF; Suttie JW
    Biochemistry; 1982 May; 21(10):2406-11. PubMed ID: 6807339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin K epoxide reductase activity and its inhibition by warfarin in young and old rats.
    Hallak HO; Wedlund PJ
    Drug Metab Dispos; 1991; 19(1):278-9. PubMed ID: 1673414
    [No Abstract]   [Full Text] [Related]  

  • 32. Formation of 3-hydroxy-2,3-dihydrovitamin K1 in vivo: relationship to vitamin K epoxide reductase and warfarin resistance.
    Preusch PC; Suttie JW
    J Nutr; 1984 May; 114(5):902-10. PubMed ID: 6726460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B16 tumor cells contain a warfarin sensitive vitamin K1 2,3 epoxide reductase.
    Uitendaal MP; Thijssen HH; Drittij-Reijnders MJ; Hoeijmakers MJ
    Biochem Biophys Res Commun; 1986 Jun; 137(3):1015-20. PubMed ID: 3729947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro effect of beta-lactam antibiotics and N-methyltetrazolethiol on microsomal vitamin K epoxide reductase in rats.
    Kawamoto K; Touchi A; Sugeno K; Matsubara T
    Jpn J Pharmacol; 1988 Jun; 47(2):169-78. PubMed ID: 3199593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification of a vitamin K epoxide reductase that catalyzes conversion of vitamin K 2,3-epoxide to 3-hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinone.
    Mukharji I; Silverman RB
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2713-7. PubMed ID: 3857611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical basis of warfarin and bromadiolone resistance in the house mouse, Mus musculus domesticus.
    Misenheimer TM; Lund M; Baker EM; Suttie JW
    Biochem Pharmacol; 1994 Feb; 47(4):673-8. PubMed ID: 8129744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver.
    Cain D; Hutson SM; Wallin R
    Thromb Haemost; 1998 Jul; 80(1):128-33. PubMed ID: 9684798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depression of liver microsomal vitamin K epoxide reductase activity associated with antibiotic-induced coagulopathy.
    Matsubara T; Touchi A; Harauchi T; Takano K; Yoshizaki T
    Biochem Pharmacol; 1989 Aug; 38(16):2693-701. PubMed ID: 2764989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.
    Yamanaka Y; Yamano M; Yasunaga K; Shike T; Uchida K
    Thromb Res; 1990 Jan; 57(2):205-14. PubMed ID: 2315885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.